AB Science

AB

FR0010557264

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.968 EUR

Average target price

6.895 EUR

Spread / Average Target

+250.36%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
AB SCIENCE	-44.64%	108M
KYOWA KIRIN CO. LTD.	+10.08%	9.12B
SK BIOPHARMACEUTICALS CO., LTD.	-17.63%	4.8B
YUHAN CORPORATION	+0.73%	3.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+16.55%	3.72B
INDIVIOR PLC	+27.76%	2.58B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.11%	2.36B
BETTA PHARMACEUTICALS CO., LTD.	-30.09%	2.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.15%	1.86B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:26 2024-04-19 am EDT			5-day change	1st Jan Change
1.968 ^EUR	-1.11%		-9.93%	-44.64%

Apr. 04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
Apr. 03	AB Science: reconsideration possible for masitinib in ALS	CF

AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	Apr. 04	MT
AB Science: reconsideration possible for masitinib in ALS	Apr. 03	CF
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS	Apr. 03	CI
AB Science: encouraging results for masitinib	Mar. 13	CF
Transcript : AB Science S.A. - Special Call	Mar. 04
AB Science: share price falls, negative opinion in Canada	Feb. 27	CF
AB Science: share price falls, CHMP verdict postponed	Jan. 29	CF
AB Science: medical use patent for masitinib	Jan. 15	CF
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis	Jan. 15	CI
Transcript : AB Science S.A. - Special Call	Nov. 30
AB Science: project selected for public funding	Nov. 27	CF
AB Science S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Global markets live: Kingfisher, Tesla, Ulta Beauty, Amazon, Target...	23-09-19
AB Science Expects European Marketing Authorization for Rare Neurological Disease Drug in Early 2024	23-09-19	MT
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
AB Science Wins European Patent for Prostate Cancer Drug	23-06-27	MT
AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer	23-06-26	CI
France's AB Science Secures Canadian Patent for Rare Neurological Disease Drug	23-06-02	MT
AB Science's Revised Application for Rare Neurological Disorder Drug Accepted for Review in Canada	23-05-10	MT
AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
AB Science SA Summarizes Presentation on Masitinib in Amyotrophic Lateral Sclerosis at American Academy of Neurology 2023 Annual Meeting in Boston, USA	23-04-27	CI
Global markets live: Tesla, Bed Bath & Beyond, J&J, Comcast, CME Group...	23-04-24
AB Science Raises EUR15 Million to Fund Masitinib Development	23-04-24	MT
AB Science Plans EUR15 Million Boost to Capital in Support of New Strategy	23-04-24	MT

AB Science

Equities

AB